Yazılar

Autopilot Verdict Hits Tesla’s Robotaxi Ambitions, Raises Safety Concerns

/in /tarafından

A Florida jury has ordered Tesla (TSLA.O) to pay approximately $243 million in damages following a fatal 2019 crash involving a Model S equipped with Autopilot driver-assistance software. The verdict, which found Tesla’s Autopilot system defective, poses a significant setback to CEO Elon Musk’s plans to rapidly expand the company’s robotaxi network across the U.S.

Tesla maintains that the driver was solely at fault and plans to appeal the decision. This ruling comes amid ongoing federal investigations and recalls linked to Tesla’s autonomous driving technology. It could intensify regulatory scrutiny, making it harder for Tesla to convince state authorities that its self-driving tech is safe and ready for broad deployment.

Experts say the verdict may increase pressure on regulators to impose stricter safety checks before approving autonomous vehicle services. Legal and industry analysts warn the ruling threatens Musk’s goal of offering robotaxi service to half of the U.S. population by year-end, a critical component as Tesla faces slowing demand for its older electric vehicle models and backlash over Musk’s political views.

Palantir’s software underpins Tesla’s robotaxi plans. Success will depend on earning regulators’ and consumers’ trust in the Full Self-Driving (FSD) software, an advanced system capable of city street navigation and autonomous maneuvers, building on the original Autopilot system used primarily on highways.

Tesla’s FSD updates have continued since 2019. Analysts at Piper Sandler noted that the verdict does not directly affect the latest versions of Tesla’s FSD software.

Regulatory and Industry Context:
Developing safe, fully autonomous vehicles has proven more challenging and costly than anticipated. Many companies, such as General Motors’ Cruise unit, have faced setbacks or changed strategy. Musk’s approach relies mainly on cameras and AI rather than expensive sensors like lidar and radar used by rivals such as Waymo and Zoox.

Tesla launched a limited robotaxi trial in June in Austin, Texas, deploying about a dozen Model Y SUVs monitored by safety drivers. Musk aims to rapidly scale this service nationwide, targeting coverage of half the U.S. population within months, contrasting with Waymo’s cautious multi-year rollout.

Tesla is currently seeking regulatory approval in multiple states, including California, Nevada, Arizona, and Florida. Officials have not commented on the verdict’s impact.

Case Details:
The lawsuit concerned a crash where a Tesla Model S, with Autopilot engaged, ran a stop sign and collided with a parked Chevrolet Tahoe. The driver admitted distraction but no alerts were received before the incident. The jury found Autopilot had a defect and held Tesla partly liable.

Tesla has historically won or settled most Autopilot-related lawsuits out of court. This verdict stands out and may influence several pending cases.

Investors and legal experts warn the ruling could delay regulatory progress and damage Tesla’s image at a critical time for its autonomous vehicle ambitions.

Waymo Targets 2026 Launch of Autonomous Ride-Hailing Service in Washington, D.C.

/in /tarafından

Alphabet’s self-driving division, Waymo, has announced its plans to roll out its fully autonomous ride-hailing service in Washington, D.C. by 2026. The company, which has already expanded its service to several major U.S. cities, aims to introduce its driverless technology to the U.S. capital in the coming year.

Expanding Autonomous Services to Washington, D.C.

Waymo has been progressively moving its self-driving vehicles to Washington, D.C. since January, with more vehicles expected to be deployed over the coming weeks. While the city currently does not allow for fully autonomous vehicles without a human behind the wheel, Waymo intends to work closely with local policymakers to develop the necessary legal framework for the service.

Waymo One, the company’s self-driving ride-hailing service, has already gained significant traction in other cities, including San Francisco, Phoenix, Los Angeles, and Austin, where it provides over 200,000 paid trips weekly. The company plans to expand to Atlanta and Miami next before launching in Washington, D.C.

Regulatory Challenges and Funding

The announcement comes amid growing interest in autonomous vehicle deployment, especially in Washington, D.C., where federal regulators and lawmakers are located. Tech companies, including Waymo, have urged the government to expedite vehicle approvals and establish clearer regulations for autonomous vehicles.

In October 2024, Waymo closed a $5.6 billion funding round led by its parent company, Alphabet, which will help support the expansion of its self-driving services despite ongoing safety concerns raised by regulators.

Safety Concerns and Recalls

Waymo’s autonomous vehicles have faced scrutiny from the National Highway Traffic Safety Administration (NHTSA), which opened an investigation in May 2024 after receiving multiple reports of the company’s robotaxis exhibiting unexpected behavior, including traffic violations and collisions. In response to these incidents, Waymo issued several recalls, including a recall in June 2024 of 672 vehicles after one of its driverless cars hit a utility pole in Phoenix.

Despite these challenges, Waymo claims that based on data from over 50 million rider-only miles (80.5 million kilometers), its vehicles have been involved in 81% fewer injury-causing crashes compared to average human drivers.

Conclusion

Waymo’s plans for the 2026 launch of its autonomous ride-hailing service in Washington, D.C. represent a significant milestone in the development of self-driving technology. While the company faces regulatory hurdles and safety concerns, it continues to push forward with its vision for a future without human drivers.

Novo Nordisk Raises Alarm Over Deaths Linked to Compounded Versions of Weight-Loss Drug Wegovy

/in /tarafından

Novo Nordisk recently acknowledged reports indicating that 10 people have died and over 100 have been hospitalized after using compounded versions of its popular weight-loss and diabetes drugs, Wegovy and Ozempic, chemically known as semaglutide. The company’s CFO, Karsten Munk Knudsen, confirmed awareness of these cases, which emerged from the FDA’s adverse events database. The database does not establish direct causality between compounded semaglutide and the deaths but serves as a preliminary warning mechanism for potential health risks.

The U.S. allows compounding pharmacies to create alternatives to brand-name drugs that are temporarily in short supply, achieved by mixing or altering drug ingredients. Until recently, Novo Nordisk’s semaglutide drugs, Wegovy and Ozempic, were on the FDA’s shortage list due to high demand, especially within the United States. This shortage situation permitted compounding pharmacies to manufacture copies.

When asked to elaborate, a Novo Nordisk spokesperson directed attention to the FDA’s adverse events database, which has recorded 10 deaths linked to compounded semaglutide over the past two years, though none identified a direct cause. The adverse event reports are submitted by doctors, patients, and drug manufacturers and are intended as preliminary safety signals rather than concrete scientific evidence. Reports often lack detailed information and may include multiple entries for the same incident, making it challenging to draw definitive conclusions.

Novo Nordisk CEO Lars Fruergaard Jorgensen expressed concern about the potential lack of regulatory oversight on compounded versions of these medications, especially given the FDA’s stringent surveillance of Novo Nordisk’s official products. He criticized the sale of compounded semaglutide variants online and in “health spas,” bypassing the formal supply chain used by Novo Nordisk and its competitor Eli Lilly for distributing their FDA-approved medications. “It beats me,” Jorgensen remarked, emphasizing the potential risks posed by unregulated products.

In October, Novo Nordisk requested that the FDA restrict compounding pharmacies from producing copycat versions of Wegovy and Ozempic, arguing that the complexities involved in manufacturing these drugs might exceed the capabilities of some compounders, leading to safety concerns. Knudsen added that Novo Nordisk had observed multiple safety issues with some compounded products, reinforcing the need for stricter regulatory measures.

Despite Novo Nordisk’s efforts to meet demand, Wegovy and Ozempic remain listed on the FDA’s shortages list, though all dose strengths are currently noted as available. Knudsen highlighted the significant investments made to expand production capacity and the ongoing dialogue with the FDA, expressing optimism that these drugs may eventually be removed from the shortage list, which could limit compounding pharmacies’ ability to create alternatives.